Dr. Barbara Hickingbottom is the Senior Vice President, Clinical Development at Fate Therapeutics and is leading the company’s clinical development efforts. Dr. Hickingbottom has more than 25 years of life sciences experience in clinical development, medical affairs, and registration strategy, and has led the development of novel biologics, including bispecific antibodies and cytokine therapies, in the areas of oncology and autoimmunity. Dr. Hickingbottom was previously the Chief Medical Officer at AskGene. Prior to her time at AskGene, she was Head of Clinical Development at Xencor. Before joining Xencor, Dr. Hickingbottom held senior positions at several leading biopharmaceutical companies. Dr. Hickingbottom received her M.D. from the Tufts University School of Medicine and completed her internship and residency in pathology at Stanford. She also received a J.D. from the Harvard Law School and, prior to medical school, practiced law in Boston.
